Newsletter Life Sciences Voice Top Five Newsletter

Life Sciences Voice Top Five Newsletter


Read ahead to find the latest news in the pharma & biotech industry with Beta Bionics securing $100M in funding for its medical device replicating the functioning of the pancreas, the European Commission approving another COVID-19 vaccine booster, a migraine therapy by AbbVie receiving marketing authorization, and other top news!

Beta Bionics Secures $100 Million for Artificial Pancreas Expansion 

Beta Bionics, a company in the field of medical technology, has managed to secure an impressive $100 million in funding. This financial boost comes hot on the heels of receiving crucial FDA approval for their groundbreaking artificial pancreas system, iLet. This innovative device aims to revolutionize the lives of those dealing with diabetes by automating the delicate balancing act of insulin and glucagon delivery. With this substantial funding injection, Beta Bionics can now embark on an ambitious expansion plan, bringing them one step closer to their mission of significantly improving the daily lives of individuals grappling with diabetes.

Asensus and NVIDIA Collaborate on Digital Surgical AI

Asensus Surgical, a leader in surgical technology, and NVIDIA, a powerhouse in high-performance computing, have joined forces in a landmark collaboration set to transform the world of surgery. By marrying Asensus Surgical’s cutting-edge surgical robotics platform with NVIDIA’s exceptional computing capabilities, the duo is committed to creating next-generation AI-driven solutions for the field of surgery. This partnership represents a pivotal stride forward in the realm of digital surgery, promising to enhance precision and patient outcomes through the integration of artificial intelligence.

TrialBee’s New Tool Aims to Expedite Clinical Trial Recruitment Delays

TrialBee, a player in the realm of clinical trial recruitment technology, has unveiled a tool aimed at tackling the persistent issue of delays in clinical trial recruitment. Leveraging the power of artificial intelligence and data analytics, this innovative tool streamlines the process of matching eligible patients with suitable clinical trials. By doing so, it holds the potential to significantly accelerate the development of new medical treatments and therapies, ultimately benefiting both patients and the medical research community.

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron Variant

The European Commission has granted approval for an updated version of the Pfizer-BioNTech COVID-19 vaccine, specifically tailored to combat the Omicron XBB-1.5 variant. This development underscores the remarkable agility of vaccine manufacturers in responding to emerging viral variants. By adapting their vaccine formulations to address evolving strains of the virus, they ensure that individuals continue to have access to effective protection against the ever-changing landscape of COVID-19.

Marketing Authorization Granted for AbbVie’s Migraine Therapy, Aquipta

AbbVie, a prominent pharmaceutical company, has achieved a significant milestone by receiving marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its migraine therapy, Aquipta. For individuals who have long endured the debilitating effects of migraines, this authorization brings a glimmer of hope. Aquipta represents a potential breakthrough in migraine management, offering a new avenue for relieving the symptoms and improving the overall quality of life for those afflicted by this condition. The marketing authorization now paves the way for wider accessibility to this promising treatment, bringing much-needed relief to migraine sufferers.

Exclusive Sponsor: Axtria – the leading global provider of cloud software and data analytics solutions to the life sciences industry.

Latest news

Health-Tech Startup Evidation Opens Up Its Symptom-Logging App To Track Migraine Discomfort

California health technology firm Evidation is making its app for logging symptoms more open to track how migraine symptoms....

According to research, Gilead’s long-acting HIV medication is superior to Truvada

Gilead Sciences (GILD.O) announced that in a late-stage trial, its injectable treatment, lenacapavir, was 40.2% more effective in preventing...

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you